Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGK1 | P00558 | 4/20 | 0.51 |
| ▸ | PGK2 | P07205 | 4/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 13/20 | 0.46 |
| ▸ | PTPN2 | P17706 | 5/20 | 0.46 |
| ▸ | PTPN6 | P29350 | 5/20 | 0.46 |
| ▸ | PTPN11 | Q06124 | 4/20 | 0.46 |
| ▸ | PTPRB | P23467 | 3/20 | 0.46 |
| ▸ | PTPRC | P08575 | 3/20 | 0.46 |
| ▸ | CDC25A | P30304 | 1/20 | 0.44 |
| ▸ | PTPN5 | P54829 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6946531 | 0.89 | PTPN1 (0.55) | PGK1PGK2PTPN1PTPN2PTPN6 | |
| SCHEMBL4316972 | 0.78 | PTPN1 (0.74) | PGK1PGK2PTPN1PTPN2PTPN6 | |
| SCHEMBL6946534 | 0.78 | PTPN1 (0.47) | PGK1PGK2PTPN1PTPN2PTPN6 | |
| SCHEMBL5163594 | 0.77 | PGK1 (0.59) | PGK1PGK2PTPN1PTPN2PTPN6 | |
| SCHEMBL7660739 | 0.77 | PGK1 (0.59) | PGK1PGK2PTPN1PTPN2PTPN6 | |
| SCHEMBL7591720 | 0.76 | PGK1 (0.57) | PGK1PGK2PTPN1PTPN2PTPN6 | |
| SCHEMBL7188019 | 0.76 | PGK1 (0.57) | PGK1PGK2PTPN1PTPN2PTPN6 | |
| SCHEMBL5892025 | 0.75 | PGK1 (0.56) | PGK1PGK2PTPN1PTPN2PTPN6 | |
| SCHEMBL5163005 | 0.74 | PTPN5 (0.57) | PGK1PGK2PTPN1PTPN2PTPN6 | |
| SCHEMBL5165050 | 0.73 | PGK1 (0.50) | PGK1PGK2PTPN1PTPN2PTPN6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6174874-B1 | ANTIDIABETIC,-CARCINOGENIC AGENTS; IMPROVING GLUCOSE TOLERANCE/INSULIN-SENSITIVITY; PREVENTING/TREATING OBESITY AND NEURODEGENERATIVE DISEASES; E.G. 1,3-BIS-((PHOSPHONODI-FLUOROMETHYL)PHENYL)-2-DICARBOXYPROPANE | MERCK FROSST CANADA & CO. (CA) | 2001-01-16 | — | — | US | disclosed |